Live Breaking News & Updates on Ultiple Sclerosis Relapsing Remitting

Stay updated with breaking news from Ultiple sclerosis relapsing remitting . Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Blood Test for MS Activity Gets FDA Breakthrough Designation

Roche s Elecsys NfL test is intended to be used as an aid in detection of disease activity in adults with relapsing-remitting multiple sclerosis or secondary progressive multiple sclerosis. ....

Matt Sause , Drug Administration , Elecsys Neurofilament Light Chain , Medscape Medical News , Elecsys Nfl , Multiple Sclerosis Ms , Multiple Sclerosis , Multiple Sclerosis Progression , Als Progression , Multiple Sclerosis Prognosis , S Prognosis , Ultiple Sclerosis Prognostic Factors , S Prognostic Factors , Secondary Progressive Multiple Sclerosis , Relapsing Remitting Multiple Sclerosis , Ultiple Sclerosis Relapsing Remitting , Us Food And Drug Administration , United State ,

Stem Cell Transplants for Early MS: Who Benefits Most?

Researchers are exploring HSCT as a rescue therapy in early-stage MS. But there s no consensus on best practices. ....

City Of , United Kingdom , Antonio Scalfari , Richard Nicholas , Imperial College London , Imperial College Healthcare , University Of Bergen Norway , Multiple Sclerosis Ms , Multiple Sclerosis , Transplantation Stem Cell , Ransplantation Hematopoietic Stem Cell , Hematopoietic Stem Cell Transplantation , Stem Cell Transplantation , Stem Cell Therapy , Herapy Stem Cell , Monoclonal Antibody , Relapsing Remitting Multiple Sclerosis , Ultiple Sclerosis Relapsing Remitting , Clinical Researc ,

MS-Tailored Weight Loss Program Achieves Meaningful Results

People with multiple sclerosis and obesity can achieve substantial weight loss, leading to improved mobility and quality of life, with a specially designed program, new trial results suggest. ....

University Of Kansas Medical Center , United States , New Jersey , East Hanover , Kansas City , Sharong Lynch , Brianm Sandroff , Neurorehabilitation Research Laboratory , Kessler Foundation , National Multiple Sclerosis Society , European Committee For Treatment , Outcomes Research Institute , National Ms Society , Department Of Neurology , National Institutes Of Health , American Heart Association , Research In Multiple Sclerosis , Us Centers For Disease , Americas Committee For Treatment , Kansas Medical Center , Joint European Committee , Multiple Sclerosis Americas Committee , Multiple Sclerosis , Patient Determined Disease Steps , Disease Control , African American ,

AI Tool Reveals MS Drug Interactions, Offers Safer Options

Clinicians prescribing a drug for patients with multiple sclerosis who are on multiple treatments may in future use AI to identify potential interactions and suggest safer options, new data suggest. ....

Pavan Bhargava , Michael Hecker , European Committee For Treatment , Rostock University Medical Center , Research In Multiple Sclerosis , Johns Hopkins Precision Medicine Center , Department Of Neurology , Americas Committee For Treatment , Joint European Committee , Multiple Sclerosis Americas Committee , Multiple Sclerosis , Medscape Medical News , Multiple Sclerosis Ms , Multiple Sclerosis , Drug Interactions , Relapsing Remitting Multiple Sclerosis , Ultiple Sclerosis Relapsing Remitting , Artificial Intelligence , A I , Healthcare And Medical Technology , Ealth And Medical Tech , Ealth And Med Tech , Ealth And Medical Technology , Biologic Therapy , Adverse Effects , Side Effects ,

FDA Okays First Biosimilar for Multiple Sclerosis

Sandoz s natalizumab-sztn injection (Tyruko) is on par with Biogen s Tysabri (natalizumab) for treatment of relapsing forms of MS, the FDA said in approving the first biosimilar to treat MS. ....

Paulr Lee , Drug Administration , Division Of Neurology , Drug Evaluation , Medscape Medical News , Eastern European , Expanded Disability Status Scale , Multiple Sclerosis Ms , Multiple Sclerosis , Relapsing Remitting Multiple Sclerosis , Ultiple Sclerosis Relapsing Remitting , Biosimilar Drugs , Follow On Biologics , Secondary Progressive Multiple Sclerosis , Biologic Therapy , Us Food And Drug Administration , Nited States Food And Drug Administration , Clinically Isolated Syndrome , Crohns Disease , Progressive Multifocal ,